sgRNAs targeting Gnb2 were significantly depleted over a 16-day incubation period, confirming a potential oncogenic function of wild-type Gnb2 in MLL-AML (P = 0.00366) (Fig. 8d, e). This evidence concerns the gene KMT2A and acute myeloid leukemia.